| SAXAGLIPTIN HYDROCHLORIDE | Astrazeneca | ||
| 2.5 mg and 5 mg; Tablet, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| Used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems | |||
|
Yes
| |||
| Onglyza | Patent 1 | Patent 2 | Patent 3 |
|---|---|---|---|
| ********* | ******* | ********* ** **** *** | ******* |
| ********* | ******* | ****** ***** (**** ** **) | ******* |
| ****** | ******* | ****** ***** (**** ** **) | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ********* | *** \ ** | *** **, **** | ********* ** **** *** | **** | ******* **** **** *** *** **** |
| ********* | *** \ *** | *** **, **** | ******* ***** **** ** ** | ******** | ******** ** **** **, **** |
| ****** | *** \ ** | *** **, **** | ******* ***** **** ** ** | ********* ******** | ******* **** **** *** *** **** |
Download ParaIV Report